Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4202-4205

  Bowman, J C ^a   Abruzzo, G K ^a   Flattery, A M ^a   Gill, C J ^a   Hickey, E J ^a   Hsu, M J ^a   Nielsen Kahn, J ^a   Liberator, P A ^a   Misura, A S ^a   Pelak, B A ^a   Wang, T C ^a   Douglas, C M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS NIDULANS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; IN VIVO STUDY; KIDNEY INFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIDULANS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED DBA; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845269301     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00485-06     Document Type: Article

References (31)

1. Abruzzo, G. K., C. J. Gill, A. M. Flattery, L. Kong, C. Leighton, J. G. Smith, V. B. Pikounis, K. Bartizal, and H. Rosen. 2000. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:2310-2318.
2. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.
3. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.
4. Barchiesi, F., E. Spreghini, A. Santinelli, A. W. Fothergill, S. Fallani, E. Manso, E. Pisa, D. Giannini, A. Novelli, M. I. Cassetta, T. Mazzei, M. G. Rinaldi, and G. Scalise. 2005. Efficacy of caspofungin against Aspergillus terreus. Antimicrob. Agents Chemother. 49:5133-5135.
5. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
6. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. Clinical and Laboratory Standards Institute, Wayne, Pa.
7. Cooke, F. J., E. Terpos, J. Boyle, A. Rahemtulla, and T. R. Rogers. 2003. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin. Microbiol. Infect. 9:1238-1241.
8. Dotis, J., and E. Roilides. 2004. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int. J. Infect. Dis. 8:103-110.
9. Douglas, C. M. 2001. Fungal beta(1,3)-D-glucan synthesis. Med. Mycol. 39(Suppl. 1):55-66.
10. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
11. Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409.
12. Graybill, J. R., S. Hernandez, R. Bocanegra, and L. K. Najvar. 2004. Anti-fungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother. 48:3715-3719.
13. Hachem, R. Y., D. P. Kontoyiannis, M. R. Boktour, C. Afif, C. Cooksley, G. P. Bodey, I. Chatzinikolaou, C. Perego, H. M. Kantarjian, and I. I. Raad. 2004. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101:1594-1600.
14. Hickey, E., G. Abruzzo, J. Bowman, C. Douglas, C. Gill, P. Liberator, A. Misura, B. Pikounis, and K. Bartizal. 2005. Caspofungin versus amphotericin B treatment of Aspergillus, fumigatus in kidneys of chronically immunosuppressed infected mice. Therapy 2:615-621.
15. Howell, A., J. Midturi, M. Sierra-Hoffman, J. Carpenter, D. Hurley, and R. Winn. 2005. Aspergillus flavus scleritis: successful treatment with voriconazole and caspofungin. Med. Mycol. 43:651-655.
16. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
17. Imai, J., G. Singh, B. Fernandez, K. V. Clemons, and D. A. Stevens. 2005. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J. Antimicrob. Chemother. 56:166-171.
18. Kahn, J. N., M. J. Hsu, F. Racine, R. Giacobbe, and M. Motyl. 2006. Caspofungin susceptibility in Aspergillus and non-Aspergillus moulds: inhibition of glucan synthase and reduction of beta-D-1,3-glucan levels in culture. Antimicrob. Agents Chemother. 50:2214-2216.
19. Kartsonis, N. A., A. J. Saah, C. Joy Lipka, A. F. Taylor, and C. A. Sable. 2005. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. 50:196-205.
20. Kelly, R., E. Register, M. J. Hsu, M. Kurtz, and J. Nielsen. 1996. Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. J. Bacteriol. 178:4381-4391.
21. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
22. Maertens, J., I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, F. B. Petersen, C. A. Sable, N. A. Kartsonis, A. Ngai, A. Taylor, T. F. Patterson, D. W. Denning, and T. J. Walsh. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
23. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
24. O'Sullivan, C. E., M. Kasai, A. Francesconi, V. Petraitis, R. Petraitiene, A. M. Kelaher, A. A. Sarafandi, and T. J. Walsh. 2003. Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis. J. Clin. Microbiol. 41:5676-5682.
25. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
26. Perea, S., and T. F. Patterson. 2002. Invasive Aspergillus infections in hematologic malignancy patients. Semin. Respir. Infect. 17:99-105.
27. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
28. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
29. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
30. Segal, B. H., E. S. DeCarlo, K. J. Kwon-Chung, H. L. Malech, J. I. Gallin, and S. M. Holland. 1998. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77:345-354.
31. Singh, G., J. Imai, K. V. Clemons, and D. A. Stevens. 2005. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob. Agents Chemother. 49:1369-1376.